Results 211 to 220 of about 168,270 (320)

Comparison of fully versus partially covered metal stents in endoscopic ultrasound‐guided hepaticogastrostomy for malignant biliary obstruction (with video)

open access: yesDigestive Endoscopy, EarlyView.
Background Endoscopic ultrasound‐guided hepaticogastrostomy (EUS‐HGS) using a fully covered metal stent (FCMS) or partially covered metal stent (PCMS) is performed to manage unresectable malignant biliary obstruction (MBO) following unsuccessful endoscopic retrograde cholangiopancreatography.
Sung Hyun Cho   +4 more
wiley   +1 more source

Bone metaplasia in gallbladder lithiasis: an astonishing clinical phenomenon of a rare case. [PDF]

open access: yesJ Surg Case Rep
Mahmoudi M   +5 more
europepmc   +1 more source

Endoscopic findings of gallbladder lesions evaluated with image‐enhanced endoscopy: A preliminary study using resected gallbladders [PDF]

open access: yesDEN Open
Abstract The diagnosis of gallbladder (GB) lesions relies on imaging findings. Transpapillary cholangioscopy can potentially be used to diagnose GB lesions; however, the images obtained remain unclear. This study aimed to characterize the endoscopic findings of GB lesions. We examined the endoscopic features of GB lesions in 50 consecutive patients who
Kobayashi K   +19 more
europepmc   +2 more sources

Rare Cases Related to the Gallbladder

open access: bronze, 1956
Satoshi Saitô   +2 more
openalex   +2 more sources

Laparoscopic cholecystectomy for a gallstone within an intrahepatic gallbladder: A case report in Abidjan. [PDF]

open access: yesInt J Surg Case Rep
Adon AA   +5 more
europepmc   +1 more source

Real‐world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To assess real‐world use of Saxenda® (liraglutide 3.0 mg) and off‐label use of Victoza® (liraglutide 1.2 mg/1.8 mg) for weight management and Saxenda® posology in the United Kingdom. Their similar doses and formulation pose a risk of inadvertent use due to their use for different indications.
Tarita Murray‐Thomas   +5 more
wiley   +1 more source

PI5P4K inhibitors: promising opportunities and challenges

open access: yesThe FEBS Journal, EarlyView.
Developing inhibitors is like climbing a steep, challenging mountain. PI5P4K inhibitors hold significant promise for the treatment of cancer, immune disorders, and neurological diseases. However, the path to success is fraught with hurdles, and researchers are therefore required to apply their expertise to overcome critical “checkpoints.” While some ...
Koh Takeuchi   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy